RB1 mutations, which portend worse outcomes,38 were lower, while SMARCA4 alterations, which may be a marker for susceptibility to CDK4/6 inhibition,39 was significantly higher in NSCLC with MTAP loss. This evidence concerns the gene RB1 and non-small cell lung carcinoma.